627101-57-9

Upstream product

• 905589-59-5 (3,4-dimethoxoxyphenyl)methyl 2,2,2-trichloroacetimidate 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 212051-39-3 methyl 3-(3,4-dimethoxy-benzyloxy)-2-(R)-methyl-propionate 

Downstream Products

• 627101-46-6 (R)-1-(3,4-Dimethoxy-benzyloxy)-2-methyl-pentan-3-one 
• 627101-59-1 propionic acid (1R,5R)-5-(tert-butyldimethyl-silanyloxy)-1-[(1R,2R,3R)-4-(3,4-dimethoxy-benzyloxy)-1,3-dimethyl-2-triethylsilanyloxy-butyl]-(2E,6E,8E)-9-iodo-3-methyl-nona-2,6,8-trienyl ester 
• 627101-60-4 (6E,10E,12E)(2R,3S,4R,5R,9R)-9-(tert-butyldimethyl-silanyloxy)-1-(3,4-dimethoxy-benzyloxy)-13-iodo-2,4,7-trimethyl-3-triethylsilanyloxy-trideca-6,10,12-trien-5-ol 
• 627101-49-9 (6E,10E,12E)(2R,3S,4R,5R,9R)-9-(tert-butyldimethyl-silanyloxy)-1-(3,4-dimethoxy-benzyloxy)-13-iodo-5-methoxy-2,4,7-trimethyl-3-triethylsilanyloxy-trideca-6,10,12-triene 
• 627101-58-0 propionic acid (1R,5R)-5-(tert-butyldimethyl-silanyloxy)-1-[(1S,2R,3S)-4-(3,4-dimethoxy-benzyloxy)-1,3-dimethyl-2-hydroxy-butyl]-(2E,6E,8E)-9-iodo-3-methyl-nona-2,6,8-trienyl ester 
• 627101-48-8 (6E,10E,12E)(2R,4R,5R,13R)-9-(tert-butyldimethyl-silanyloxy)-1-(3,4-dimethoxy-benzyloxy)-5-hydroxy-13-iodo-2,4,7-trimethyl-trideca-6,10,12-trien-3-one 
• 889454-40-4 (2R,5S,6R,7S,9S,10E,13R,14E,16E)-13-(tert-butyldimethylsilyloxy)-1-(3,4-dimethoxybenzyloxy)-17-bromo-5-hydroxy-9-methoxy-7-triethylsilyloxy-2,6,11-trimethyl-heptadeca-10,14,16-trien-3-one 
• 889454-48-2 6-[10-bromo-6-(tert-butyldimethylsilyloxy)-2-methoxy-4-methyl-deca-3,7,9-trienyl]-4-(tert-butyldimethylsilyloxy)-2-[2-(3,4-dimethoxybenzyloxy)-1-methyl-ethyl]-2-methoxy-5-methyl-tetrahydro-pyran 
• 889454-44-8 propionic acid (1S,2E,5R,6E,8E)-5-(tert-butyldimethylsilyloxy)-1-[(1R,2S)-4-(3,4-dimethoxybenzyloxy)-1-methyl-2-triethylsilyloxy-butyl]-9-bromo-3-methyl-nona-2,6,8-trienyl-ester 
• 889454-56-2 6-[10-bromo-6-(tert-butyldimethylsilyloxy)-2-methoxy-4-methyl-deca-3,7,9-trienyl]-2-[2-(3,4-dimethoxybenzyloxy)-1-methyl-ethyl]-2-methoxy-5-methyl-tetrahydro-pyran-4-ol 
• 889454-55-1 (2R,3S,5S,6E,9R,10E,12E)-9-(tert-butyldimethylsilyloxy)-1-(3,4-dimethoxybenzyloxy)-13-bromo-2,7-dimethyl-3-triethylsilyloxy-trideca-6,10,12-trien-5-ol 
• 889454-45-9 (2R,3S,5S,6E,9R,10E,12E)-9-(tert-butyldimethylsilyloxy)-1-(3,4-dimethoxybenzyloxy)-5-methoxy-13-bromo-2,7-dimethyl-3-triethylsilyloxy-trideca-6,10,12-triene 
• 889454-54-0 propionic acid (1S,2E,5R,6E,8E)-5-(tert-butyldimethylsilyloxy)-1-[(1R,2S)-4-(3,4-dimethoxybenzyloxy)-1-methyl-2-hydroxy-butyl]-9-bromo-3-methyl-nona-2,6,8-trienyl-ester 
• 889454-42-6 (2R,5S,6E,9R,10E,12E)-9-(tert-butyldimethylsilyloxy)-1-(3,4-dimethoxybenzyloxy)-5-hydroxy-13-bromo-2,7-dimethyl-trideca-6,10,12-trien-3-one 

Relevant academic research and scientific papers

Stereocontrolled Total Synthesis of (-)-Callipeltoside A

(Equation presented) A highly stereocontrolled total synthesis of the cytotoxic macrolide (-)-callipeltoside A has been achieved in 23 steps (4.8% overall). Notable features include a novel asymmetric vinylogous aldol reaction to install the C13 stereocen

Total synthesis and stereochemical reassignment of (+)-dolastatin 19, a cytotoxic marine macrolide isolated from Dolabella auricularia

Using conformational analysis and biogenetic considerations, a revised configurational assignment for the cytotoxic marine macrolide dolastatin 19 is proposed, together with its validation by completion of the first total synthesis. Key features of the hi